242 related articles for article (PubMed ID: 1331485)
21. Clinical trials with the topoisomerase I inhibitors.
Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
[TBL] [Abstract][Full Text] [Related]
22. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
McDonald AC; Brown R
Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
[TBL] [Abstract][Full Text] [Related]
23. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
Boscia RE; Korbut T; Holden SA; Ara G; Teicher BA
Int J Cancer; 1993 Jan; 53(1):118-23. PubMed ID: 8416195
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
25. Review of phase I clinical studies with topotecan.
Rowinsky EK; Verweij J
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
[TBL] [Abstract][Full Text] [Related]
26. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase I inhibitors in the treatment of colorectal cancer.
Rothenberg ML; Blanke CD
Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
[TBL] [Abstract][Full Text] [Related]
28. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Petit T; Izbicka E; Lawrence RA; Bishop WR; Weitman S; Von Hoff DD
Ann Oncol; 1999 Apr; 10(4):449-53. PubMed ID: 10370788
[TBL] [Abstract][Full Text] [Related]
29. Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.
Siu LL; Attardo G; Izbicka E; Lawrence R; Cerna C; Gomez L; Davidson K; Finkle C; Marsolais C; Rowinsky EK; Von Hoff DD
Ann Oncol; 1998 Aug; 9(8):885-91. PubMed ID: 9789612
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
31. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells.
Hanauske AR; Degen D; Hilsenbeck SG; Bissery MC; Von Hoff DD
Anticancer Drugs; 1992 Apr; 3(2):121-4. PubMed ID: 1356030
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Gerrits CJ; de Jonge MJ; Schellens JH; Stoter G; Verweij J
Br J Cancer; 1997; 76(7):952-62. PubMed ID: 9328159
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
34. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Kaufmann SH
Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
[TBL] [Abstract][Full Text] [Related]
35. Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
Pizao PE; Smitskamp-Wilms E; Van Ark-Otte J; Beijnen JH; Peters GJ; Pinedo HM; Giaccone G
Biochem Pharmacol; 1994 Sep; 48(6):1145-54. PubMed ID: 7945408
[TBL] [Abstract][Full Text] [Related]
36. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
Mitsui I; Kumazawa E; Hirota Y; Aonuma M; Sugimori M; Ohsuki S; Uoto K; Ejima A; Terasawa H; Sato K
Jpn J Cancer Res; 1995 Aug; 86(8):776-82. PubMed ID: 7559102
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
38. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Nagourney RA; Sommers BL; Harper SM; Radecki S; Evans SS
Br J Cancer; 2003 Nov; 89(9):1789-95. PubMed ID: 14583785
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]